LUCD Lucid Diagnostics Inc. Expected net earnings per share growth this year
Lucid Diagnostics Inc. (LUCD) is attracting leading biologists, fostering a culture of precision to combat oncology. Growth is based on the commercialization of molecular tests and the optimization of laboratories. The YoY earnings per share dynamics reflect market cycles, where the value of 36.90 describes the current level. High confidence among gastroenterologists grants the brand a lifesaver status thanks to the painless EsoGuard method.
Financial and market metric breakdowns for Lucid Diagnostics Inc. (LUCD)
- current quotes and average value forecast:
- market capitalization data:
- shareholders' equity book value data:
- debt and liquidity details:
Total Debt to Equity Ratio Lucid Diagnostics Inc.|LUCD - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient luciddx.com|LUCD - Company Aggregate Debts|Debt to Book Value Ratio Lucid Diagnostics, Inc|LUCD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Lucid Diagnostics|Immediate Liquidity Ratio luciddx.com
- earnings and valuation multiples information:
LUCD - Net Profit|Company Profit Forecast Lucid Diagnostics Inc.|LUCD - P/E Multiple|Forward P/E Multiple Lucid Diagnostics, Inc|LUCD - PEG Multiple|Enterprise Value to EBITDA Multiple Lucid Diagnostics, Inc|LUCD - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Lucid Diagnostics|LUCD - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months luciddx.com|LUCD - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Lucid Diagnostics Inc.
Fundamental valuation:Lucid Diagnostics, Inc.
Lucid Diagnostics Inc. (LUCD) maintains stability by recruiting highly qualified biologists to advance precision cancer diagnostics, establishing a foundation for long-term capitalization. By analyzing the annual growth rate of earnings per share, an investor assesses the net profit per share relative to the previous period, isolating real financial progress from market volatility to determine the asset's fair value.
Key competitors
A - Expected net earnings per share growth this year|Earnings per share growth in current year Quest|Illumina Platform (ILMN) - Expected net earnings per share growth this year|Earnings per share growth in current year Exact Sciences (EXAS)|Earnings per share growth in current year RVTY (revvity.com)|Bio-Rad - Net earnings per share growth this year|Earnings growth in current year Anbio Biotechnology Ltd NNNN|Sterigenics - Earnings growth in current year|QuidelOrtho Inc. (QDEL) - Net earnings per share growth this year|OPK: Earnings growth in current year|CDNA - Expected net earnings per share growth this year|MRVI (Maravai LifeSciences Holdings, Inc.) - Earnings growth in current year|Earnings per share growth this year FLGT (Fulgent Genetics Inc)|Net earnings per share growth this year LAB (Fluidigm)|CTKB (Cytek Corp) - Earnings per share increase in current year|Earnings growth in current year OSUR (OraSure Technologies)|XGN: Earnings per share growth this year|MDxHealth - Earnings growth in current year|Expected net earnings per share growth this year Prenetics Global PRE|IMDX: Earnings growth in current year|Trinity Biotech (TRIB) - Earnings growth in current year|PRPH (ProPhase Labs, Inc.) - Earnings growth in current year|AIMD - Net earnings per share change in current year|Earnings per share growth in current year Co-Diagnostics (CODX)|Heart Test Laboratories, Inc. - Earnings per share growth this year|Earnings per share growth in current year Biomerica, Inc BMRA|Cardio Diagnostics Holdings Inc. (CDIO) - Earnings per share growth rate in current year|ONCO - Earnings per share growth in current year|Expected net earnings per share growth this year viraxbiolabs.com VRAX|BJDX (Bluejay Diagnostics, Inc.) - Net earnings per share growth this year|AWH: Net earnings per one share growth for the current year|AXDX (Accelerate Diagnostics, Inc) - Earnings growth in current year|CENTOGENE N.V. (CNTG) - Expected net earnings per share growth this year|Earnings growth in current year ENZ|Net earnings per share growth this year fresh2.co FRES|Earnings per share growth in current year Genetic Technologies Limited GENE|Expected net earnings per share growth this year 23andMe Holding Co (ME)|PMD: Net earnings per share growth this year
